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Abstract
Neurocognitive disorders are emerging as a possible
complication in patients infected with HIV. Even if
asymptomatic, neurocognitive abnormalities are
frequently detected using a battery of tests. This
supported the creation of asymptomatic
neurocognitive impairment (ANI) as a new entity. In a
recent article published in BMC Infectious Diseases,
Magnus Gisslén and colleagues applied a statistical
approach, concluding that there is an overestimation
of the actual problem. In fact, about 20% of patients
are classified as neurocognitively impaired without a
clear impact on daily activities. In the present
commentary, we discuss the clinical implications of
their findings. Although a cautious approach would
indicate a stricter follow-up of patients affected by
this disorder, it is premature to consider it as a proper
disease. Based on a review of the data in the current
literature we conclude that it is urgent to conduct
more studies to estimate the overall risk of
progression of the asymptomatic neurocognitive
impairment. Moreover, it is important to understand
whether new biomarkers or neuroimaging tools can
help to identify better the most at risk population.
Please see related article: http://www.biomedcentral.
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Introduction
As HIV-infected patients are living longer thanks to
highly active antiretroviral therapy (HAART), our objec-
tive as clinicians is to offer them a life expectancy and a
quality of life comparable to individuals not infected by
HIV. Unfortunately, several complications are emerging
as a consequence of premature aging, an effect of persis-
tent or non-reversible immune-activation and concomi-
tant risk factors (such as smoking or use of recreational
drugs) or co-infections (such as chronic hepatitis C) [1].
HIV-associated neurocognitive disorders (HAND) could
be one of the most important complications, the accepted
prevalence of HAND today is approximately 50% despite
the overall efficacy of HAART [2]. Indeed, several
patients are being diagnosed with a broad spectrum of
neurocognitive impairments ranging from subtle altera-
tions that are only evident through specific tests (that is,
asymptomatic neurocognitive impairment (ANI)) to mild
neurocognitive disorders (MND) that start having dele-
terious effects on patients’ daily activities [3]. Moreover,
despite the fact that HIV-associated dementia (HAD) is
currently controlled [4], there is a concern that neuro-
cognitive disorders will worsen even on HAART, leading
to a resurgence of this problem in the future. This con-
cern is based on patients on HAART who have neurolo-
gical deficits despite persistent undetectable HIV RNA in
plasma [5], but with detectable HIV RNA in the cere-
brospinal fluid (CSF) [6], neuroinflammation in the CSF
[7], or ß-amyloid deposition in the brain [8].
The American Academy of Neurology (AAN) updated
the nosology of HAND in 2007, introducing ANI as a
new pathological entity [9]. The panel itself recom-
mended using this classification only for research.
Indeed, this entity had been evaluated in only two studies
concerning a small number of ANI-suffering patients
before consensual but not unanimous approval [10,11].
Notwithstanding this consideration, it has already been
adopted into clinical practice. For instance, the Italian
guidelines for HIV disease management suggest starting
HAART in all patients with HAND, a recommendation
that is stronger for those with MND but also applies to
those with ANI [12].
In the accompanying paper published in BMC Infec-
tious Diseases, Gisslèn et al. [13] emphasize that a high
proportion of HIV infected patients (about 20%) may be
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tomatic) using the AAN criteria. According to this clas-
sification, ANI is characterized by neuropsychological
testing outcomes that are at least one standard deviation
below the mean of normative scores in at least two cog-
nitive areas among at least five domains. The authors
highlighted that, according to this criterion, even in a
general population with a normal distribution of the
neuropsychological testing outcomes, almost 16% of the
individuals will be defined as abnormal. The bottom line
is that the definition of ANI may lead to an unaccepta-
ble false-positive rate and that therefore the actual pro-
blem is overestimated.
Discussion
Statistical considerations
From a statistical point of view, in addition to the results of
the paper by Gisslèn et al. [13], it is interesting to note that
in the case of independent tests exhibiting a Gaussian dis-
tribution the probability of having all scores of the five
tests more than one standard deviation from their mean is
only about 0.42 (as demonstrated both by the probability
of only one test being abnormal, which is 0.84134, raised
to five and by simulations that we have performed); so, the
probability of having something not ‘absolutely normal’,
according to the AAN proposed threshold (one standard
deviation lower than the mean), is less favorable than tos-
sing a coin. Of course, the very high probability value of
making a diagnosis of ANI together with the above result
immediately emphasizes the problem of the false positive
proportion and, consequently, the need for a critical con-
sideration of the validity of diagnostic criteria based on the
‘z-score’. Indeed, it is common to obtain some z-score
values associated with a low probability value, meaning
that it is practically impossible from a Gaussian distribution
[14]. Moreover, the Gaussian model could be limited since
it may include impossible negative values; this happens, for
instance, for values lower than two standard deviations less
than the mean of the raw values (that is, the neuropsycho-
logical test results without adjusting for the normative
values). According to these considerations, it would be
more advisable not to rely upon some asymptotic results
from the statistical theory (central limit theorem) leading
to the Gaussian model, but to refer to skewed distributions
and to calculate non-parametric thresholds (0.95 quantile,
for example, or its lower 95% confidence limit). We actu-
ally think that, when an immediate medical treatment is
not required as in the case of an ANI, knowing that a
patient is under some relevant quantiles (0.5, 0.10 or 0.25)
of the ‘reference population’ can be more informative for
monitoring his/her follow-up than a result based on a para-
metric model (one standard deviation less than the mean),
which may be too restrictive and not able to fit well with a
set of real observations.
Clinical considerations
From a clinical point of view, it is important to highlight
that, being asymptomatic, ANI is not an overt disease, so
it would be clinically relevant only if it had been correlated
with signs of definite pathologies or if it had been shown
to be predictive of more severe neurocognitive impair-
ments. Although a cross-sectional study demonstrated a
correlation between pathological evidence of HIV ence-
phalitis at autopsy and ANI diagnosed ante-mortem, this
study is limited because it involved only the most compro-
mised patients who died, so results are not transferable to
the general population [11]. Moreover, it is a little discon-
certing to find that, using the AAN criteria, even 16% to
19% HIV-negative young people about 35 years old who
were used as controls had neurocognitive disorders in the
s t u d yb yH e a t o net al. [3]. Lastly, in the five years after
ANI was defined [9], no single study was performed to
assess its predictive value for MND or HAD. Therefore, it
remains plausible that patients with ANI have a greater
risk of progression to MND/HAD than those without, but
this is currently uncertain and may be difficult to demon-
strate for several reasons:
(i) since neurocognitive impairment has been corre-
lated with a variety of conditions (such as psychiatric
disorders or psychoactive medications, recreational
drugs, alcohol abuse, chronic hepatitis C, metabolic
abnormalities, vascular disease, and even potential
neurotoxicity of antiretroviral drugs) [15-22], it is diffi-
cult to properly select the cases where the effect of
HIV is predominant, which are more probably des-
t i n e dt oM N Da n dH A D ;
(ii) HAART is likely to improve the evolution of
HIV-associated neurocognitive impairment [23], so
studies on the natural history of this disease are dif-
ficult to conduct;
(iii) neurocognitive impairment may fluctuate over
time [24], implying that the disease may sponta-
neously recover or that the prodromic stages of
d e m e n t i a( A N Ia n dM N D )a r en o ts t r o n g l yp r e d i c -
tive. This has been already proven for mild cognitive
impairment in aging-associated cognitive decline
[25];
(iv) the pathogenesis of neurocognitive disorders
involves multiple signs [26], whose relationships are
for the most part not elucidated. It is possible that
neurocognitive disorders comprise heterogeneous
conditions whose prognosis and treatment are differ-
ent. So the question is: can new biomarkers and/or
neuroimaging techniques help disentangle the differ-
ent nosological entities?
Several studies have investigated biomarkers and
found that signs of persistent immune-activation in the
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tion, neopterin, neurofilaments, IL-6, cholesterol, myoi-
nositol) [7,27-30] or chronic peripheral activation
(indicated by CD14, CD16 or lipopolysaccharide)
[31-33] correlated with neurological impairment. As for
neuroimaging, recently developed tools are promising.
For instance, magnetic resonance spectroscopy is able to
show a decreased level of N-acetyl aspartate, a sign of
mature neurons and their axonal processes, in the basal
ganglia of patients infected by HIV; moreover, decreased
levels of N-acetyl aspartate were accompanied by
increased choline and myoinositol as signs of cell turn-
over and inflammation [34]. Interestingly, these markers
may be restored by HAART, and this may be correlated
with improvement of neurocognition [35]. It has to be
seen whether incorporation of these biomarkers or neu-
roimaging results into diagnostic algorithms may
improve the clinical predictive value and relevance of
subtle neurocognitive impairments such as ANI.
Considerations for clinical management
In the meantime, what should clinicians do when a
diagnosis of ANI is made? Clearly, with the current
diagnostic definition, ANI should not be assumed to be
synonymous with an overt pathology or a major risk for
HAD. Some experts recommend, as a cautious
approach, to retest patients with ANI with the aim of
identifying early on, any sign of progression of the neu-
rocognitive disorder [12]. However, this practice should
not excessively preoccupy our patients, leading to anxi-
ety and depression for a condition that may not be sig-
nificant. This is important in light of the fact that some
p a t i e n t s ,u pt o5 3 % ,s u f f e rf r o mA N I( a sc u r r e n t l y
defined) [5].
Conclusions
In principle, the burden of ANI as a possible disease is
huge in the HIV infected population. However, at pre-
sent, this condition is more theoretical than real because
it has not been validated for its relevance in clinical
practice. Appropriately designed studies are urgently
needed to understand whether this ANI is clinically
meaningful or a false alarm both for patients and for
physicians. In other words, a clinical validation of ANI
is a priority before strong clinical recommendations are
made. Since this condition may be heterogeneous, both
in terms of pathogenesis and outcome, it has to be
ascertained whether new biomarkers and neuroimaging
techniques can help identify the most at risk patients. In
the meantime, a cautious approach is recommended to
monitor patients with ANI for progression of their neu-
rological impairment, but this should be done without
worrying our patients too much.
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